



April 1, 2021

Re: Changes to specialty medical drug coverage effective July 1, 2021*

Effective July 1, 2021,* we will make changes to the specialty medical drugs we cover to help ensure our customers have access to affordable and quality health care. As a result, ELIGARD[®], Fensolvi[®], LUPRON DEPOT[®], LUPRON DEPOT-PED[®], and TRELSTAR[®] will require medical precertification and may be subject to site-of-care management. We will also require medical precertification for FIRMAGON[®] and Zoladex[®].

What this means to you and your patients with Cigna coverage

Beginning July 1, 2021, for coverage under the medical benefit, you must obtain approval through the precertification process. This applies to both new starts and individuals already receiving the drugs listed above. Submission for reimbursement without precertification may result in denied claims.

Based on our plan utilization records, one or more of your patients will be affected by these changes. They will be sent letters this month and may contact you directly to discuss the precertification review process. Medical necessity requirements are outlined in the coverage policies available on the Cigna for Health Care Professionals website (CignaforHCP.com > Get questions answered: Resource > Coverage Policies).

If you have any questions, please call Cigna Customer Service at **800.88Cigna (882.4462)**.

Thank you for your shared commitment to helping our customers better manage their medication therapies and improve their health outcomes.

Sincerely,

A handwritten signature in cursive script that reads "Young Fried".

Young Fried, PharmD, MSP
Chief Pharmacy Officer

* For Texas- and Louisiana-insured customers, the effective date may be deferred until the plan renewal date, as required by state law.